A long term follow-up of a randomized trial comparing interferon-α with busulfan for chronic myelogenous leukemia

This publication has 11 references indexed in Scilit:

• Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous Leukemia
  New England Journal of Medicine, 1997
• A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase
  Blood, 1995
• UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response
  The Lancet, 1995
• Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon-α Therapy
  Annals of Internal Medicine, 1995
• Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia
  New England Journal of Medicine, 1994
• Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583 [see comments]
  Blood, 1993
• Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia
  The American Journal of Medicine, 1990
• Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia
  Blood, 1988
• Clinical investigation of human alpha interferon in chronic myelogenous leukemia
  Blood, 1987
• Analysis of survival by tumor response.
  Journal of Clinical Oncology, 1983